The Trispecific TCE or Bispecific ADC: A New Way to Deeply Deplete B-Cells Potentially for Oncology & Autoimmune Diseases
- Examine the potential of trispecific T-cell engagers TCEs and bispecific ADCs as next-generation strategies for deep B-cell depletion across oncology and autoimmune indications
- Understand the mechanistic advantages of multi-specific modalities in enhancing precision, potency, and durability compared to traditional approaches
- Explore translational insights and early data shaping the clinical promise of these innovative platforms for redefining treatment paradigms